Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2021
Institutional positions in Pharvaris N.V. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- −5 vs. Q1 2021
- Shares held
- 22.0M
- −29.3K (−0.1%) vs. Q1 2021
- Total value
- $406.3M
- −$210.2M (−34.1%) vs. Q1 2021
- New holders
- 2
- 9 more added
- Sold out
- 7
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,261,926 | $60.8M | 8.21% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $59.3M | 3.88% | 00.0% | Unchanged |
| FMR LLC | 3,258,217 | $59.2M | 0.00% | +490,490+17.7% | Added |
| General Atlantic LLC | 2,420,155 | $45.1M | 0.32% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,391,517 | $43.5M | 0.13% | −28,638−1.2% | Reduced |
| venBio Partners LLC | 2,303,310 | $42.9M | 5.06% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 1,032,757 | $19.2M | 0.34% | 00.0% | Unchanged |
| VR Adviser, LLC | 902,882 | $16.8M | 2.04% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 744,863 | $13.6M | 0.53% | −119,280−13.8% | Reduced |
| Pictet Asset Management Ltd | 557,059 | $10.1M | 0.01% | +3,874+0.7% | Added |
| Eventide Asset Management, LLC | 541,563 | $9.84M | 0.13% | +41,563+8.3% | Added |
| Avidity Partners Management LP | 400,000 | $7.45M | 0.20% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 364,142 | $6.78M | 2.67% | −300,000−45.2% | Reduced |
| Millennium Management LLC | 196,967 | $3.58M | 0.00% | −33,933−14.7% | Reduced |
| Novo Holdings A/S | 111,144 | $2.07M | 0.09% | +61,144+122.3% | Added |
| Opaleye Management Inc. | 79,837 | $1.49M | 0.25% | +79,837 | New |
| Farallon Capital Management, L.L.C. | 71,020 | $1.29M | 0.01% | −128,980−64.5% | Reduced |
| BlackRock Inc. | 33,382 | $622.0K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 27,792 | $518.0K | 0.00% | +3,364+13.8% | Added |
| Perceptive Advisors LLC | 27,000 | $503.0K | 0.01% | 00.0% | Unchanged |
| Morgan Stanley | 19,984 | $372.0K | 0.00% | +15,149+313.3% | Added |
| Geode Capital Management, LLC | 18,643 | $338.0K | 0.00% | +2,259+13.8% | Added |
| JPMorgan Chase & Co | 16,434 | $299.0K | 0.00% | +2,560+18.5% | Added |
| Compagnie Lombard Odier SCmA | 15,030 | $274.0K | 0.01% | 00.0% | Unchanged |
| Caas Capital Management LP | 13,479 | $251.0K | 0.01% | −36,521−73.0% | Reduced |
| Ensign Peak Advisors, Inc | 5,000 | $91.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 561 | $11.0K | 0.00% | +561 | New |
| Bank of America Corp | 550 | $10.0K | 0.00% | +50+10.0% | Added |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −39,008−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −22,650−100.0% | Sold out |
| Zimmer Partners, LP | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Rokos Capital Management LLP | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −116−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −32−100.0% | Sold out |